Methods and Reagents Useful for Verification of the Integrity of a Urine Sample and the Detection of Counterfeit Urine
20220381698 · 2022-12-01
Inventors
Cpc classification
G01N33/94
PHYSICS
G01N33/4875
PHYSICS
G01N33/52
PHYSICS
International classification
Abstract
The problem of detecting whether a urine sample is true human urine or a counterfeit urine product is solved by the use of reagent systems that detect two markers normally present in human urine. The markers acid phosphatase and alkaline phosphatase catalyze the substrates thymolphthalein monophosphate and p-nitrophenol phosphate, respectively. These substrates are formulated as spot tests on a dip stick or as reagents for use in automated chemical analyzers. The presence of the markers can be qualitatively detected by color-changes in the sample, formed by the pH-specific chromogens that result from catalysis of the substrates with the markers. The control reagent can further indicate whether a counterfeit urine product contains one or both of the chromogens.
Claims
1. A reagent, adapted to be utilized in an automated analyzer to detect a marker in a urine sample, the reagent comprising: a first component having an alkaline pH; a second component having an acid pH that comprises p-nitrophenyl phosphate, which is catalyzed by the marker in the urine sample to produce a chromogen.
2. The reagent according to claim 1, wherein the marker in the urine that catalyzes the p-nitrophenyl phosphate is alkaline phosphatase.
3. The reagent according to claim 2, wherein the color is spectrophotometrically measurable at approximately 405 nm.
4. The reagent according to claim 1, wherein the first component has a pH of about 10.2+/−0.05.
5. The reagent according to claim 1, wherein the second component has a pH of about 6.5+/−0.01.
6. A method for utilizing an automated analyzer to detect a marker in a urine sample, the method comprising: a) obtaining a reagent, according to claim 1; b) combining an aliquot of the urine sample with the first component of the reagent to form a test sample; c) further combining the test sample with the second component of the reagent to form a reacted sample; and d) detecting formation of a chromogen in the reacted sample that is indicative of the presence of the marker in the urine sample.
7. The method according to claim 6, wherein the marker is alkaline phosphatase and the chromogen is p-nitrophenol.
8. The method according to claim 6, further comprising allowing the automated analyzer to warm the test sample.
9. The method according to claim 8, wherein the formation of a yellow color detectable by the automated analyzer in the test sample is indicative of an indicator dye in the urine sample.
10. The method according to claim 6, wherein the first component has a pH of about 10.2+/−0.05.
11. The method according to claim 6, wherein the second component has a pH of about 6.5+/−0.01.
12. A method for utilizing an automated analyzer to detect an adulterated urine sample, the method comprising: a) obtaining a reagent according to claim 1; b) combining an aliquot of a urine sample with the first component of the reagent to form a test sample; and c) detecting the formation of a color in the test sample, which indicates an adulterated urine sample.
13. The method according to claim 12, wherein the color is detected at about 405 nm.
14. The method according to claim 12, wherein the adulterated urine sample comprises an indicator dye activated by the alkalinity of the first component to form the color.
15. The method according to claim 12, further comprising allowing the automated analyzer to warm the test sample, wherein the color is detected during warming of the test sample.
16. The method according to claim 12, wherein the first component has a pH of about 10.2+/−0.05.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0021] In order that a more precise understanding of the above recited invention can be obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. The drawings presented herein may not be drawn to scale and any reference to dimensions in the drawings or the following description is specific to the embodiments disclosed. Any variations of these dimensions that will allow the subject invention to function for its intended purpose are considered to be within the scope of the subject invention.
[0022]
[0023]
[0024]
[0025]
[0026]
DETAILED DISCLOSURE
[0027] The subject invention provides testing procedures for detecting, individually or concurrently, two markers unique to human urine. The testing regimen can utilize reagent systems for determining whether a urine sample, usually one submitted for drugs-of-abuse (DOA) testing, is true urine—of human origin—or a counterfeit (artificial) urine product.
[0028] More specifically, the subject invention provides a method and corresponding reagents for detecting the presence of two markers as determinants of whether a sample is true urine or a counterfeit urine product. The assay techniques of the subject invention employ acid phosphatase (AP) and alkaline phosphatase (ALP), two markers that are normally present in true urine, which react with specific substrates to provide a qualitative indication of the constitution of the sample. Preferred embodiments of the subject invention utilize a unique combination of testing and a control methodology by which an absence of the markers is detected, thereby indicating that the sample is not true urine and potentially a counterfeit urine product.
[0029] Advantageously, these markers have a labile nature that makes them unsuitable, or at least impractical, as additives to counterfeit urine products. The constituents are temperature sensitive causing them to degrade within a few days and become undetectable, often before the counterfeit urine product can be used. The reagents according to the subject invention are safe and non-toxic.
[0030] The embodiments of the subject invention are further advantageous in that they can be formulated as dip stick tests, as well as for use with automated laboratory equipment, such as clinical analyzers, particularly spectrophotometric-based analyzers. The use of automated laboratory equipment can make analysis of numerous samples more efficient, economical, and accurate, while a dipstick method can be useful for quick confirmatory tests, often where fewer samples need to be tested.
[0031] The markers AP and ALP have significantly different labilities, in that, they degrade at different rates. The lability of a sample is further affected by the temperature at which the sample is stored. Even ambient temperatures, for more than one day, can begin to affect the markers and other constituents, including DOA, in the sample. The common rule of thumb is that a 10° C. increase doubles the normal rate of decomposition of a sample and a 10° C. decrease reduces decomposition to about half the normal rate. Thus, a sample of urine, and the constituents and any DOA therein, would be expected to remain stable for about three days if kept at 2-10° C. A urine sample maintained at an ambient temperature of about 20-30° C. would be expected to remain stable for about one day.
[0032] The Food and Drug Administration has established c-GMP guidelines for DOA testing protocols, which are required to be followed by certified testing laboratories. One criteria is that samples be tested within established time frames. The testing methodology of the subject invention can be used to determine the age of a urine sample. AP normally degrades at a faster rate than ALP in a urine sample. The reagent systems of the subject invention can be used to detect the presence of both markers, AP and ALP, and include a control that can indicate whether the sample was adulterated. If the results of the assay show the presence of both AP and ALP and the control does not indicate tampering, i.e., no change in color of the control, then the sample is likely true urine and was recently collected and/or properly handled and stored. If the results of the assay show the presence of ALP, does not show the presence of AP, and the control does not indicate tampering, then it is likely that the sample is true urine, but was collected too long before the test was conducted and the AP has degraded to a point of non-detection. Alternatively the sample was improperly handled and/or stored.
[0033] Human urine has high concentrations of acid phosphatase and alkaline phosphatase. There are a number of substrates that are catalyzed by either acid or alkaline phosphatase. The substrates p-nitrophenyl phosphate and thymolphthalein monophosphate are unique because they are each catalyzed by AP and/or ALP and both have alkaline-activated chromogens, as illustrated in the following Table 1.
TABLE-US-00001 TABLE 1 Substrates for use in Detecting Acid and Alkaline Phosphatases Chromogen Reacts with Reacts with Alkaline pH Urinary Acid Urinary Alkaline Color Indication Substrate activated? Phosphatase? Phosphatase? (Absorbance nm) p-nitrophenyl phosphate Yes Yes Yes Yellow (405-410) Thymolphthalein Yes Yes +/− Blue (600) monophosphate b-napthol phosphate Yes Yes +/− Yellow (410) or red (540) with diazo phenolphthalein Yes +/− +/− Red (540) monophosphate phenol phosphate No Yes Yes Red (540) with diazo or blue (600-700) with Folin reagent glycerol phosphate No Yes Yes Yellow (410) (or blue 600-700 with additional reagent)
[0034] The subject invention utilizes the urine markers acid phosphatase (AP) and alkaline phosphatase (ALP) as catalysts for two substrates that are each hydrolyzed under distinctly different pH conditions. The substrate thymolphthalein monophosphate is hydrolyzed by and preferred for detecting AP. Conversely, the substrate p-nitrophenyl phosphate is hydrolyzed by either the AP or ALP markers and is employed by the embodiments of the subject invention for detecting alkaline phosphatase. Testing for AP is preferred for samples that are relatively fresh, i.e., one to two days old, and testing for ALP is preferred for samples that are a few days older.
[0035] The substrate thymolphthalein monophosphate is shown below:
##STR00001##
[0036] Thymolphthalein monophosphate is catalyzed by AP at between approximately pH 4 to approximately pH 6. When combined with an aliquot of a sample of true urine, AP in the urine hydrolyzes this substrate thereby producing free thymolphthalein. Thymolphthalein is a colorless product at the acid pH necessary for hydrolysis. When exposed or subjected to alkaline conditions, thymolphthalein exhibits a blue color. Thymolphthalein monophosphate is catalyzed to form thymolphthalein as follows (Equation I):
##STR00002##
[0037] Another substrate utilized with embodiments of the subject invention is p-nitrophenylphosphate:
##STR00003##
[0038] P-nitrophenyl phosphate is catalyzed by urinary alkaline phosphatase (ALP) at between approximately pH 8 and approximately pH 11. P-nitrophenyl phosphate is also catalyzed by urinary acid phosphatase at between approximately pH 5 and approximately pH 6. When added to a sample of true urine, alkaline phosphatase (ALP) in the urine hydrolyzes the p-nitrophenol phosphate substrate, thereby producing free p-nitrophenol. P-nitrophenol turns yellow at the pH necessary for hydrolysis, thus is self-indicating. Acid phosphatase (AP) also catalyzes the hydrolysis of p-nitrophenol phosphate to liberate p-nitrophenol, which under the acid is colorless at the acid pH required for this AP reaction. Thus, a second step that alkalinizes the solution is necessary to activate p-nitrophenol as a chromagen that indicates the hydrolysis of p-nitrophenyl phosphate.
[0039] P-nitrophenylphosphate is catalyzed by ALP as follows (Equation II):
##STR00004##
[0040] Thus, both thymolphthalein and p-nitrophenol are chromogens that are color-activated under alkaline conditions, such that thymolphthalein turns blue and p-nitrophenyl turns yellow.
[0041] Automated analyzers typically utilize liquid reagents that are robotically added to sample vials. In one embodiment, the reagents of the subject invention are formulated as liquids for use in an automated analyzer. When a sample treated according to the subject invention is analyzed spectrophotometrically, the blue color produced by thymolphthalein is absorbed at a wavelength of approximately 600 nm. The yellow color produced by p-nitrophenol is absorbed at a wavelength of between approximately 405 nm and approximately 410 nm.
[0042] The stability of the thymolphthalein monophosphate and p-nitrophenyl phosphate substrates makes them useful for dip stick or spot tests. Spot tests are well-known in the art and can have a liquid, semi-solid, or solid transport medium. For the sake of providing a visual representation of the embodiments of the subject invention, reference will be made to a dipstick methodology, as shown in
[0043] In one embodiment, the spot test is a paper strip or what is often referred to as a “dip stick.” The dip stick can be prepared with “spots” or areas thereon comprising the corresponding substrate reagents or control reagent. In one embodiment, the p-nitrophenyl phosphate is present on a Test spot in at least five times the concentration utilized in the liquid reagent form. In another embodiment, the thymolphthalenin monophosphate is present on a Test spot in at least five times the concentration utilized in the liquid reagent form. In a further embodiment, a Control spot has approximately 5% Brij 35, which is greater than the percentage used in the liquid reagent.
[0044] According to embodiments of the subject invention, a dip stick is treated with thymolphthalein monophosphate, p-nitrophenyl phosphate, or both, as shown in
[0045] Embodiments of the subject invention utilize reagent systems, which include substrate reagents that are catalyzed by either AP and/or ALP and a color-developer reagent that activates or enhances the appearance and color of the resulting chromogen. The reagent system embodiments can also utilize a control reagent, which advantageously confirms the presence or absence of one or both of the chromogens.
[0046] The reagent systems of the subject invention are effective when utilized individually to indicate the presence of one or both urine-related markers. The reagent systems can be most advantageous when utilized concurrently, as part of dual reagent system, because they provide a definitive, qualitative indication that a sample comprises true urine or a counterfeit urine product.
[0047] A further advantage of the reagent systems of the subject invention is the ability to determine the age of a urine sample, which can be used to indicate the viability of the sample and, further, the reliability of test results conducted on a sample. Testing laboratories can also utilize the results of such aging results to confirm that their sample handling protocols meet FDA guidelines.
[0048] One embodiment of a reagent system includes a substrate reagent comprising the substrate p-nitrophenyl phosphate that is buffered to between approximately pH 9.5 to approximately pH 11, which promotes formation of the chromogen in the presence of the catalyst. In a further embodiment, the reagent system includes a control reagent, which comprises no p-nitrophenol or p-nitrophenyl phosphate. The control reagent can also comprise all or most of the constituents of the substrate reagent, except for the substrate and the chromogen. In a yet further embodiment, the p-nitrophenyl phosphate reagent system has an alkaline color-developer reagent buffered to between approximately pH 9.5 to approximately pH 11. The color-developer reagent can be utilized with the control to determine whether a sample is true urine or a counterfeit urine product. This reagent system can be solidified and stabilized for use as dipstick method or the reagent system can be in liquid forms for use in clinical analyzers.
[0049]
[0050]
[0051] With regard to
[0052] With this embodiment of the p-nitrophenyl phosphate reagent system, it is also possible to detect the presence of thymolphthalein that may have been added to the sample. If the Test spot and/or the Control spot turn blue, as shown in
[0053] Efforts to defeat the above-described testing methodology for detection of p-nitrophenyl phosphate can include the addition of indicator dyes, such as, for example, Alazrin yellow and Orange II. These indicator dyes can be added to counterfeit urine products to try to mimic the yellow/orange color of the p-nitrophenol chromogen, thus giving a false-positive indication of true urine. Alazrin yellow GG and Orange II are virtually colorless at normal acid pH of urine and most known counterfeit urine products. Their color is activated under alkaline conditions. Advantageously, the Control test and alkaline color-development reagent employed by the subject invention can reveal the use of these dyes, thereby providing basis to suspect a counterfeit urine product.
[0054] The p-nitrophenyl phosphate reagent system for detection of ALP, according to the subject invention, can also be formulated as liquid reagents to be employed in chemical analyzers. When employed with a chemical analyzer, the true urine sample and a sample adulterated with an indicator dye show a distinct difference in the response times for spectrographic absorption. This difference in response times and levels can be indicative of whether a sample has been adulterated with an indicator dye. Example 3 herein provides examples of liquid reagent compositions formulated for use in clinical analyzers, which includes an alkaline-buffered Component A and a substrate-containing Component B for color-development of the chromogen p-nitrophenol.
[0055] With reference to
[0056] It can be seen in
[0057] It can be seen in
[0058] In one embodiment, a clinical analyzer can be configured with protocols that indicate a positive result for adulteration when a sample shows an immediate absorbance during the initial warming up cycle. In a further embodiment, a clinical analyzer can be configured with protocols that indicate a positive result for adulteration when a sample shows an absorbance level that is above between approximately 50% and approximately 65% of the maximum detectable absorption at 405 nm. Because of the spike in absorbance that can result when Component B is added to a sample, as discussed above, the protocols of a clinical analyzer can also be configured to indicate a result after Component B is added to the sample. Thus, the testing period during which the protocols of a clinical analyzer will evaluate a sample can occur after the addition of Component B.
[0059] In another embodiment of a reagent system, a substrate reagent that comprises thymolphthalein monophosphate and is buffered to between approximately pH 4 and approximately pH 6 reacts with AP to promote the formation of the chromogen thymolphthalein. At this pH, there will typically be no formation of the color of the chromogen. In a further embodiment, the thymolphthalein monophosphate reagent system has a color-developer reagent having an alkaline pH of between approximately 9.5 to approximately 11. This can be similar to the color developer reagent utilized with the p-nitrophenyl phosphate substrate reagent, described above. In one embodiment, the control reagent utilized with this embodiment of the reagent system can comprise all or most of the constituents of the substrate reagent, but no thymolphthalein monophosphate substrate, nor any thymolphthalein, which is the chromogen formed from p-nitrophenyl phosphate when catalyzed with AP.
[0060]
[0061] With regard to
[0062] Furthermore, with this embodiment of the reagent system, it is possible to detect the presence of p-nitropheneol that may have been added to the sample. If, after addition of the color-developer reagent the Test spot and/or the Control spot turn yellow, as shown in
[0063] In yet another embodiment, the reagent systems described above for detecting alkaline and acid phosphatase are employed concurrently, as part of a dual reagent test conducted in a single test methodology. This embodiment utilizes both substrate reagents, one containing the substrate thymolphthalein monophosphate, buffered to between approximately pH 4 and approximately pH 6, and the other containing the substrate p-nitrophenyl phosphate, buffered to between approximately pH 9.5 and approximately pH 10. The pH of each reagent promotes the catalysis of the substrates to form the respective chromogens, as discussed above. In a further embodiment, a Control reagent is utilized to detect whether one or both chromogens were added to a sample.
[0064]
[0065] With the concurrent testing methodology, when the spots are saturated with an aliquot of the sample, several reactions can occur, depending upon the nature of the sample. True urine initially turns the ALP spot yellow, caused by the ALP in the urine that catalyzes the p-nitrophenyl phosphate, which cleaves the phosphate moiety, leaving the chromogen p-nitrophenol. As discussed above, p-nitrophenol is self-indicating, in that the alkaline pH required for catalysis also activates the yellow color of the p-nitrophenol. When saturated with true urine, the AP spot and the Control spot remain colorless or can take on the same color as the sample, e.g., pale yellow. As with the embodiments described above, the possible addition of other ingredients to the sample can cause the same result of turning the ALP spot yellow. The color-developer reagent of the subject invention can be used advantageously with the Control reagent to detect these other ingredients.
[0066] Referring to
[0067] Thus, with the dual reagent system test and the testing methodology of this embodiment, true urine turns the ALP spot yellow, the AP spot blue, and the Control remains uncolored. Any other result than this can indicate that the sample is not true urine and either lacks one or both of the markers or has been adulterated likely by addition of one or both of the chromogens, or that the sample is too old or was improperly handled to provide reliable results. For example, if the ALP Test spot initially turns blue, it can indicate that the sample was adulterated with thymolphthalein, which was activated by the alkalinity of the ALP spot and not by reaction of the substrate. If, after addition of the color-developer reagent, neither the AP Test spot, nor the Control spot turn blue, the sample did not contain AP to react with the thymolphthalein monophosphate substrate. This can indicate that the sample was a counterfeit urine product or was otherwise subject to tampering, even if the ALP spot turned yellow, because true urine typically contains both AP and ALP catalysts. Counterfeit urine product or other tampering of the sample can also be suspected if, after addition of the color-developer reagent, the Control spot turns yellow or blue, an indication that the p-nitrophenol or thymolphthalein chromogen was likely added to the sample. Furthermore, if either or both the AL Test spot, the ALP Test spot, and/or the Control spot turns green, it can be an indication that both p-nitrophenol and thymolphthalein were likely added to the sample, whereby the color transformations of the yellow and blue chromogens combine to form the green color, as also shown in
[0068] Another result that can occur is the detection of one of the markers and no change in the color of the Control. More specifically, the detection of ALP, without a change in the color of the control can be obtained. Such results can indicate that the sample is true urine, but is too old or “aged” beyond a viable testing period. For example, if the testing protocol for concurrently detecting AP and ALP is utilized, a urine sample that is sufficiently fresh or that has been maintained under appropriate refrigerated conditions will produce a yellow ALP test spot, a blue AP test spot, and no change in the Control spot. If the same testing protocol is used and the urine sample is more than 2-3 days old or has not been stored under appropriate refrigeration, the ALP test spot will turn yellow, the AP test spot will show no change in color and no change in the Control spot. Furthermore, if the same testing protocol is used and there is no change in any of the spots it is an indication that either the sample is not true urine or that the sample is true urine that has aged beyond the point of obtaining any reliable test results.
[0069] The scope of the invention is not limited by the specific examples and suggested procedures and uses related herein since modifications can be made within such scope from the information provided by this specification to those skilled in the art.
[0070] A more complete understanding of the invention can be obtained by reference to the following specific examples of reagents and methods of the invention. The following examples illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted. It will be apparent to those skilled in the art that the examples involve use of materials and reagents that are commercially available, preferably ACS grade, from known sources, e.g., chemical supply houses, so no details are given respecting them.
Example 1: Preparation of Reagent System for Detection of Thymolphthalein Using Automated Analyzers
[0071]
TABLE-US-00002 Substrate Reagent: comprises Component A and Component B, which are added in a 50/50 ratio to obtain the final concentration: Component A: 17.68 grams Sodium Acetate, added to approximately 400 mL deionized water and mix until dissolved 1.6 grams Citric Acid followed with sufficient Acetic Acid (redistilled) to adjust pH to 5.6 @ 25° C. 0.2 grams Proclin 300 Add deionized water to obtain final volume of 500 mL Component B: 5.0 grams Brij 35 detergent, added to 500 mL deionized water and mix until dissolved 1.0 grams Thymolphthalein monophosphate sodium salt and mix until dissolved
Combine equal parts of Component A and Component B to obtain a final solution of Substrate Reagent. For example, 500 mL of Component A can be combined with 500 mL of Component B to obtain 1 liter of Substrate Reagent. The Substrate Reagent should be stored refrigerated at between 4°-8° C., away from light.
TABLE-US-00003 Color-Developer 20 grams Sodium Hydroxide reagent: 53 grams Sodium Carbonate (Anhydrous) Combine with 1 liter of deionized water to obtain final concentration and volume. Control Reagent: 500 mL of deionized water and 500 mL of Component B added. Calibrator: 100 Units Urinary Tract Protein 700 mL n-propanol 300 mL Deionized water 20 mg Thymolphthalein
[0072] The Urinary Tract Protein Units are arbitrary and based upon the amount of thymolphthalein produced during the time of incubation of Component A with a given ratio of component A to urine. Thus, if the time of incubation is doubled, the value of the calibrator can be cut in half. If the urine volume to Component A is lowered by decreasing sample volume, the value can be increased proportionately. The arbitrary units are intended to avoid traditional enzyme measurement and the marker(s) are to be described as Urinary Tract Glyco-proteins, so as to obscure the identity of subversion additions to the counterfeit urine.
Example 2: Parameter Settings for Detection of Thymolphthalein Using Automated Clinical Chemistry Analyzers
[0073] Following are specifications for testing a urine sample with a Mindray BS-200 automated chemical analyzer. These settings are intended as guidelines and those with skill in the art would recognize that the parameters can vary between instruments.
TABLE-US-00004 Test: TrueUrine No. User Defined Full Name: True Urine Reaction Type: Fixed-time Pri. Wave 578 nm Sec Wave 670 Direction: Increase Reac. Time: 0 and 2 Incubation Time: 20 Unit: UTP Units Precision: Integer R1: 180 R2: 40 Sample Volume: 46 Mixed Reagent Blank: Compensate: Slope: 1 Intercept: 0
Following are specifications for testing a urine sample with the AU 400, AU 400e, AU 480, AU 640, AU640e and AU680 Series automated chemical analyzers. These settings are intended as guidelines and those with skill in the art would recognize that the parameters can vary between instruments.
TABLE-US-00005 Reagent ID: User defined Test Name: True Urine Sample Volume: 30 R1 Volume: 123 R2 Volume: 43 Wavelength: Pri: 600 Sec. 700 Method: FIXED TIME Reaction Slope: POS Measuring Point 1: First 14 Last 16 Measuring Point 1: (Not Applicable) Calibration Type: 2AB Formula: Polygonal Point 1 H20 CONC: 0 Point 2 Cal CONC: 100 Note: the control procedure is the same as the Test procedure.
Example 3: Preparation of Reagent System for Detection of p-Nitrophenol Using Automated Analyzers
[0074]
TABLE-US-00006 Substrate Reagent: Alkaline Buffered and a combination of the following Component A and Component B. Component A: 31 grams 2-amino-2-methyl-1-propanol (AMP) 0.2 grams Proclin 300 0.6 grams N-hydroxyethylene-diaminetriacetic acid (HEDTA) Combine the above ingredients with approximately 800 ml deionized water and mix to dissolve to form solution #1. 0.3 grams Zinc Sulfate•7H.sub.2O Add to solution #1 and mix to dissolve to form solution #2. 0.4 grams Magnesium Acetate•4H.sub.2O Add to solution #2 and mix to dissolve to form solution #3. Adjust pH of solution #3 to 10.2 +/− 0.05 using 6N HCl, to form solution #4. 4 grams Brij 35 30% solution Add to solution #4 and mix to dissolve to form solution #5. Reagent #1 is formed by adding deionized water to solution #5 to make 1 Liter and mix to dissolve. Avoid excess exposure to air following pH adjustment. Note: This is a buffered solution. Component B: 900 mL Deionized water 0.5 grams Proclin 300 2.0 grams Imidazol 20 grams p-nitrophenol phosphate disodium salt (hydrate form) CAS No. 123359-43-3 Adjust to pH 6.5 +/− 0.01 with pure 6N HCl and bring volume to 1000 ml with deionized water. Control Reagent: Component A is replaced with deionized water and an alkaline solution, such as Component B of Example 1 above, is added as in the test. This type control is only required for dip-stick tests or where the reagent is measured as an end- point assay. If the p-nitrophenol phosphate reagent is detected by an automated device as a fixed time or kinetic assay, the initial absorbance of the reagent may be observed as a control and limits set for the initial absorbance if permitted by the automated device. Otherwise, a control as provided above must be performed to detect addition of adulterants to the counterfeit urine. Calibrator: 100 Units/L Urinary tract Protein-LD 1.0 Liter 50% Glycerol in Deionized water 1.6 grams Tris Hydrochloride 0.3 grams Magnesium Chloride 0.02 grams Zinc Chloride To the above solution add 50 Units of Alkaline phosphatase CAS RN 9001-78-9. Stock Calibrator: 140 mg p-Nitrophenol 0.2 g Proclin 300 300 mg Imidazol
[0075] Combine with approximately 800 mL of deionized water and mix to dissolve. Adjust pH to 6.5 using diluted HCl. Final Calibrator is Stock Calibrator diluted 1:250 with deionized water to obtain a Final Calibrator solution having the equivalent of 100 Enzyme Units (Urinary Tract Protein). Note: An enzyme unit (U) is specific to particular enzyme and is defined as the amount of the enzyme that catalyzes the conversion of 1 micro mole of substrate per minute.
Example 4: Parameter Settings for Detection of p-Nitrophenol Using Automated Clinical Chemistry Analyzers
[0076] Following are specifications for testing a urine sample with a Mindray BS-200 automated chemical analyzer. These settings are intended as guidelines and those with skill in the art would recognize that the parameters can vary between instruments.
TABLE-US-00007 Test: UALP No. User Defined Full Name: Alkaline Phosphatase Reaction Type: Fixed-time Pri. Wave 510 nm Sec Wave 630 Direction: Increase Reac. Time: 0 and 2 Incubation Time: 20 Unit: UALP Units Precision: Integer R1: 180 Sample Volume; 46 Mixed Reagent Blank: Compensate: Slopes: 1 Intercept: 0 Note: The control procedure for the above is the same as the test procedure, but uses the control reagents. The calibration for the above is the same as the test procedure.
[0077] Following are specifications for testing a urine sample with the AU 400, AU 400e, AU 480, AU 640, AU640e and AU680 Series automated chemical analyzers. These settings are intended as guidelines and those with skill in the art would recognize that the parameters can vary between instruments.
TABLE-US-00008 Reagent ID: User defined Test Name: True Urine LD Sample Volume: 35 R1 Volume: 120 R2 Volume: 30 Wavelength: Pri: 405 Sec. — Method: FIXED TIME Reaction Slope: POS Measuring Point 1: First 13 Last 27 Units: UTP Units Calibration Type: AA Formula: Y = AX + B Point 1 CONC: 0 Point 2 CONC: 100 Note: The control procedure for the above is the same as the Test procedure, but uses Control Reagent #1.
[0078] All patents, patent applications, provisional applications, and other publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.
[0079] Any reference in this specification to “one embodiment,” “an embodiment,” “example embodiment,” “further embodiment,” “alternative embodiment,” etc., is for literary convenience. The implication is that any particular feature, structure, or characteristic described in connection with such an embodiment is included in at least one embodiment of the invention. The appearance of such phrases in various places in the specification does not necessarily refer to the same embodiment. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.